Hey tada, I guess we shall see whether or not AZN and PFE renew merger talks. Given that AZN's pipeline is one of the weakest in pharma yet they had no presence at JP Morgan this week for the first time in a long time if ever, makes me wonder. But that is just me.
WRT a CVR, I agree that is the most likely scenario especially if someone steps up early to buy just Apabetalone. Buying the whole company however probably might make more sense to a purchaser given the $250mm in tax credits, a nice offset to upfront money, and a growing pool of potentially valuable IP. If a CVR is done after a successful read out for BetOnMace (in mid 2018 not 2019) I strongly doubt that a few hundred million dollars upfront would even come close to being enough money to get a deal done. It might be enough if someone steps up before BetOnMace is complete. Jmo